Chronic Lower Back Pain (CLBP) Market

1. DelveInsight’s‘Chronic Lower Back Pain (CLBP) Market Insights, Epidemiology and Market Forecast–2030’ report delivers an in-depth understanding of the Chronic lower back pain (CLBP), historical and forecasted epidemiology as well as the Chronic lower back pain (CLBP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Chronic Lower Back Pain (CLBP) Disease Understanding and Treatment Algorithm Chronic Low Back Pain (CLBP) Overview Chronic low back pain (CLBP) is defined as pain that persists for 12 weeks or longer, even after an initial injury or underlying cause of acute low back pain. Low back pain is very common and at one point everyone must have faced this problem. Lower back pain that is long-term (for more than 3 months) is called chronic low back pain, this condition might originate from an injury, disease, or stress on different structures of the body, and pain may vary significantly and maybe felt as bone pain, nerve pain, or muscle pain. The intensity of the pain also ranges from mild to severe. CLBP is the second leading cause of disability worldwide being major welfare and economic problem. The prevalence of CLBP in adults has increased significantly in the last decade and is continuously increasing vividly in the aging population. This condition affects men and women in all ethnic groups equally. This disease also leads to stress, depression, and anxiety. CLBP affects physically and psychologically and creates a significant amount of economic burden due to loss of function, loss of work productivity, treatment costs, and disability payments. The probable causes of CLBP are the curve of the spine, such as scoliosis or kyphosis, medical problems (fibromyalgia or rheumatoid arthritis), and piriformis syndrome (a pain disorder involving a muscle in the buttocks called the piriformis muscle). Many people with CLBP have arthritis or tear of the spine due to heavy exercise, herniated disk, or due to surgery. A herniated disc is the part of the spinal disk pushed onto the nearby nerve. Usually, these disks provide space and cushion in the spine and the loss of movement can be seen as overtime if these disks dry out and become thinner and brittle. Spinal Stenosis is the condition that arises if the spaces between the spinal nerves and spinal cord become more narrowed. Chronic Low Back Pain (CLBP) Diagnosis The diagnosis and evaluation of CLBP are very important to reduce or to rule out the risk factors due to severe injury. The first recommendation is a thorough physical examination by a well-trained physician. CLBP testing may include blood tests, radiography (X-ray imaging), bone scans, computed tomography (CT) scans, magnetic resonance imaging (MRI), diagnostic injections, bone scan, electromyography (EMG), lumbar radiography, and many other specialized tests. continued in the report….. Chronic Low Back Pain (CLBP) Treatment CLBP is the most prevalent chronic pain condition and the second most common cause of disability in the US, after arthritis or rheumatism. CLBP may be nociceptive or neuropathic or include both components. The presence of a neuropathic component is related to the more intense pain of longer duration, and a higher prevalence of co-morbidities. The actual mechanism and cause of CLBP are still unknown and due to this situation, there are no universally accepted treatment guidelines and the management of the treatment is limited. If the source of the pain is not known or can not be treated, the best option remains is to reduce the flare-ups and making the pain manageable with nonsurgical treatments. There are non-surgical treatments (physical therapy, diet, meditation, lifestyle modifications) Injection-based Treatments, pharmacologic treatments. For some patients, CLBP can be relieved by single-agent therapy, but as both nociceptive and neuropathic mechanisms are often present, combining agents with different mechanisms of action is a rational approach Analgesics, anti-inflammatory drugs, muscle relaxants, and other medications can be used to help control chronic back pain. However, most come with unwanted side effects and

2. are not intended for prolonged use. Opioid medication should not be used without a physician’s recommendation. The use of non-opioid analgesics such as acetaminophen (APAP), non-steroidal anti-inflammatory drugs (NSAIDs), or cyclooxygenase-2 (COX-2) inhibitors for initial management for LBP. The use of muscle relaxants should be avoided in patients with CLBP. Treatment of mild CLBP often begins with the use of NSAIDs and mild non-opioid analgesics, while more potent opioid analgesics are reserved for the pain of moderate-to-severe intensity. Browse full report @https://www.delveinsight.com/sample- request/chronic-lower-back-pain-clbp-market Chronic Low Back Pain (CLBP) Epidemiology The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of Chronic Lower Back Pain, Total Diagnosed Prevalent Population of Chronic Lower Back Pain, Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain, Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain, Severity Specific Diagnosed Prevalence of Chronic Lower Back Pain, Number of CLBP Patients on Prescription Medications by different Class and Number of CLBP Patients on Opioids by low dose, high dose and Overdose scenario of CLBP in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030. Key Findings   This section provides glimpses of the Chronic low back pain (CLBP) epidemiology in the 7MM. As per DelveInsight’s analysis, the total Prevalent Population of Chronic low back pain (CLBP) in the 7MM was found to be 73,802,461 in 2017. The estimates show higher prevalence of Chronic low back pain (CLBP) in the United States with 33,821,043 cases in 2017. Amongs EU5, United Kingdom show higher prevalence of Chronic low back pain (CLBP) followed by Germany and France, Italy and Spain respectively.    As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries, except Japan, wherein males occupy a larger patient pool than females Among the EU5 countries, United Kingdom had the highest diagnosed prevalent population of CLBP with 3,517,443 cases, followed by Germany and the France. On the other hand, Spain had the lowest diagnosed prevalent population. Country-wise Chronic low back pain (CLBP) Epidemiology The epidemiology segment also provides the Chronic low back pain (CLBP) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan. Chronic Low Back Pain (CLBP) Drug Chapters The drug chapter segment of the Chronic low back pain (CLBP) report encloses the detailed analysis of CLBP marketed drugs, mid phase and late stage (phase III) pipeline drugs. It also helps to understand the Chronic low back pain (CLBP) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases. Chronic Low Back Pain (CLBP) Marketed Drugs 

3. 1. Cymbalta: Eli Lilly and Company Cymbalta (Duloxetine) is a serotonin and norepinephrine reuptake inhibitor (SNRI) developed by Eli Lilly and Company. Serotonin and norepinephrine hormones present in the brain and spinal cord and are believed mediate core mood symptoms and help regulate the perception of pain. Duloxetine hydrochloride is the active ingredient of this medication. The drug is believed to be related to an increase in the action of serotonin and norepinephrine in the brain and spinal cord. People who suffer from CLBP experiences various range of pain and often struggle to find the right medication. The drug is been approved for the management of various other indication like Neuropathic Pain, Osteoarthritis, Generalized Anxiety Disorder, Major Depressive Disorder, Fibromyalgia, Diabetic Kidney Disease, etc. Products detail in the report… 2. Xtampa: Collegium Pharmaceutical Xtampa (Xtampza ER/ oxycodone) is a semisynthetic opioid analgesic derived from the baine in Germany in 1917. It is currently indicated as an immediate release product for moderate-to-severe pain and as an extended-release product for chronic moderate-to-severe pain requiring continuous opioid analgesics for an extended period. It is used for the management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Collegium has developed a novel, patented, abuse-deterrent technology platform, DETERx, which provides extended-release drug delivery while safeguarding against common methods of abuse and tampering including crushing, chewing, and heating and injecting. Xtampza ER is its first product that is utilizing the DETERx technology platform. Products detail in the report… 3. Butrans: Purdue Pharma Butrans is a transdermal patch formulation of buprenorphine. The drug is a partial agonist at µ- opioid receptors, an antagonist at kappa opioid receptors, an agonist at delta opioid receptors, and a partial agonist at ORL-1 (nociceptin) receptors. Its clinical actions result from binding to the opioid receptors. It is specifically indicated for the management of moderate-to-severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time. Products detail in the report… 4. Belbuca: BioDelivery Sciences International Belbuca (buprenorphine HCL buccal film/EN3409) is a buccal film providing transmucosal delivery of buprenorphine hydrochloride, a partial opioid agonist. The drug is a partial agonist at the µ-opioid receptor and an antagonist at the kappa-opioid receptor. It contains an opioid (narcotic) medication that is used to help manage pain severe enough to require daily, around-the-clock treatment with an opioid. Belbuca utilizes BDSI's patented BioErodible MucoAdhesive (BEMA) drug delivery technology to deliver buprenorphine, which is a Schedule III medicine. The Drug Enforcement Administration (DEA) considers Schedule III medicines to have less potential for abuse than substances in Schedule II. BEMA films were designed to rapidly deliver a dose of the drug across the mucous membranes for time-sensitive conditions or to facilitate administration of drugs with poor oral (pill) absorption. Products detail in the report… Chronic Low Back Pain (CLBP) Emerging Drugs 1. Tanezumab: Eli Lilly/Pfizer Tanezumab (also known as PF-4383119), an investigational humanized monoclonal antibody, is a potential first-in-class, non-opioid treatment, works by selectively targeting, binding to and inhibiting nerve growth factor (NGF). NGF levels increase in the body as a result of injury, inflammation or in chronic pain states. By inhibiting NGF, tanezumab may help to keep pain signals produced by muscles, skin, and organs from reaching the spinal cord and brain. The drug has a novel mechanism that acts in a different manner than opioids and other analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs), and in studies, to date, the drug has not demonstrated a risk of addiction, misuse or dependence. Products detail in the report…

4. 2. Fasinumab: Regeneron Pharmaceuticals/ Teva Pharmaceuticals Fasinumab (REGN475) is an investigational fully human IgG4κ monoclonal antibody designed to target nerve growth factor (NGF), a protein that plays a central role in the regulation of pain signaling. Blocking NGF may reduce chronic low back pain (CLBP). It is invented by Regeneron Pharmaceuticals using the company's proprietary VelocImmune technology that yields optimized fully-human antibodies. Products detail in the report… 3. MPC-06-ID: Mesoblast MPC-06-ID also known as Rexlemestrocel-L is a Mesoblast’s proprietary allogeneic mesenchymal precursor cell (MPC) product candidate, currently in the late stage of development for the treatment of chronic low back pain caused by disc degeneration (CLBP). It is being developed for patients who have exhausted conservative treatment options, may have failed epidural steroid injections and have no further treatment option other than invasive and costly surgical interventions. Products detail in the report… Request for sample pages: https://www.delveinsight.com/sample- request/chronic-lower-back-pain-clbp-market Chronic Low Back Pain (CLBP) Market Outlook Majority of the low back pain is caused by a mechanical etiology, which includes a degenerative disc or joint disease, vertebral fracture, and deformities and occur in up to 80-90% of patients, while neurogenic, inflammatory, and other less common causes make up the remainder of etiologies. If the cause of low back pain is inflammatory in nature, targeted therapy includes treatment with anti‐ inflammatory agents. This refers to early use of non-steroidal anti‐inflammatories (NSAIDs) and treatment with corticosteroids or disease‐modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis or ankylosing spondylitis. Additionally, these disease states have a higher incidence of neuropathic pain and thus may require adjuvant medications that target this specific pain type. Some patients with mechanical low back pain also have increased pain due to spasticity and may benefit from treatment with antispasmodics. The Chronic low back pain (CLBP) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Chronic low back pain (CLBP) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology. This segment gives a thorough detail of Chronic low back pain (CLBP) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, Chronic low back pain (CLBP) 7MM is expected to change in the study period 2017–2030. Key Findings  The market size of Chronic low back pain (CLBP) in the 7MM was found to be USD 4,856.6 million in 2017.

5.  Among the 7MM countries, the United States had the highest market size of Chronic low back pain (CLBP) in 2017, which accounts for approximately 62.18% of the total market. The United States Market Outlook This section provides the total Chronic low back pain (CLBP) market size and; market size by therapies in the United States. EU-5 Market Outlook The total Chronic low back pain (CLBP) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section. Japan Market Outlook The total Chronic low back pain (CLBP) market size and market size by therapies in Japan are provided. Chronic Low Back Pain (CLBP) Development Activities The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics. Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Chronic low back pain (CLBP) emerging therapies. Reimbursement Scenario in Chronic low back pain (CLBP) Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy. Competitive Intelligence Analysis We perform competitive and market Intelligence analysis of the Chronic low back pain (CLBP) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability. Some frequently asked questions: What is Chronic Lower Back Pain? Chronic low back pain is a pain that persists for 12 weeks or longer, even after an initial injury or underlying cause of acute low back pain has been treated. Low back pain is widespread, and at one point, everyone might have faced it; however, the exact cause of lower back pain is unknown. Lower back pain that is long‐term (for more than 3 months) is called chronic low back pain, this condition might originate from an injury, disease, or stress on different structures of the body, and may vary significantly and felt as bone pain, nerve pain, or muscle pain At what CAGR, Chronic Lower Back Pain market is expected to grow for the study period 2017-30? The market size of Chronic Lower Back Pain in the 7MM is expected to grow at a CAGR of 3.55% for the study period, 2017– 2030 What was the total prevalent population of Chronic Lower Back Pain in 2017?

6. The total prevalent population of Chronic Lower Back Pain in the 7MM was observed to be 73,802,461 in 2017 How is epidemiology segmented for Chronic Lower Back Pain? Total Prevalent Population of Chronic Lower Back Pain (CLBP), Total Diagnosed Prevalent Population of Chronic Lower Back Pain, Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain, Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain, Severity Specific Diagnosed Prevalence of Chronic Lower Back Pain, Number of Chronic Lower Back Pain Patients on Prescription Medications by different Class and Number of Chronic Lower Back Pain Patients on Opioids by low dose, high dose and Overdose scenario of CLBP Which companies are developing drugs for Chronic Lower Back Pain? Braeburn Pharmaceuticals, Camurus, Regeneron Pharmaceuticals, Teva Pharmaceutical, Pfizer, Eli Lilly and Company, Mesoblast, Egalet Corporation, Axsome Therapeutics, Allodynic Therapeutics, Astellas Pharma, Grünenthal GmbH, Frontier Biotechnologies, DiscGenics, Yuhan Corporation, Semnur Pharmaceuticals, Sollis Therapeutics, SpineThera, Stayble Therapeutics, AnGes MG are developing drugs for Chronic Lower Back Pain